Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 11/2014

01-11-2014 | Original Article

The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000–2010

Authors: D. Gibson-Smith, C. Klop, P. J. M. Elders, P. M. J. Welsing, N. van Schoor, H. G. M. Leufkens, N. C. Harvey, T. P. van Staa, F. de Vries

Published in: Osteoporosis International | Issue 11/2014

Login to get access

Abstract

Summary

The risk of a subsequent major or any fracture after a hip fracture and secular trends herein were examined. Within 1 year, 2.7 and 8.4 % of patients sustained a major or any (non-hip) fracture, which increased to 14.7 and 32.5 % after 5 years. Subsequent fracture rates increased during the study period both for major and any (non-hip) fracture.

Introduction

Hip fractures are associated with subsequent fractures, particularly in the year following initial fracture. Age-adjusted hip fracture rates have stabilised in many developed countries, but secular trends in subsequent fracture remain poorly documented. We thus evaluated secular trends (2000–2010) and determinants for the risk of a subsequent major (humerus, vertebral, or forearm) and any (non-hip) fracture after hip fracture.

Methods

Patients ≥50 years with a hip fracture between 2000 and 2010 were extracted from the UK Clinical Practice Research Datalink (n = 30,516). Incidence rates, cumulative incidence probabilities, and adjusted hazard ratios (aHRs) were calculated.

Results

Within 1 year following hip fracture, 2.7 and 8.4 % of patients sustained a major or any (non-hip) fracture, which increased to 14.7 and 32.5 % after 5 years, respectively. The most important risk factors for a subsequent major fracture within 1 year were the female gender [aHR 1.90, 95 % confidence interval (CI) 1.51–2.40] and a history of secondary osteoporosis (aHR 1.54, 95 % CI 1.17–2.02). The annual risk increased during the study period for both subsequent major (2009–2010 vs. 2000–2002: aHR 1.44, 95 % CI 1.12–1.83) and any (non-hip) facture (2009–2010 vs. 2000–2002: aHR 1.80, 95 % CI 1.58–2.06).

Conclusion

The risk of sustaining a major or any (non-hip) fracture after hip fracture is small in the first year. However, given the recent rise in secondary fracture rates and the substantial risk of subsequent fracture in the longer term, fracture prevention is clearly indicated for patients who have sustained a hip fracture.
Appendix
Available only for authorised users
Literature
1.
Lee YK, Lee YJ, Ha YC, Koo KH (2014) Five-year relative survival of patients with osteoporotic hip fracture. J Clin Endocrinol Metab 99:97–100PubMedCrossRef
2.
Bertran M, Norman R, Kemp L, Vos T (2011) Review of the long-term disability associated with hip fractures. Inj Prev 17:365–370CrossRef
3.
Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977–2001. J Bone Miner Res 24:1299–1307PubMedCrossRef
4.
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRef
5.
Warriner AH, Patkar NM, Yun H, Delzell E (2012) Minor, major, low-trauma, and high-trauma fractures: what are the subsequent fracture risks and how do they vary? Curr Osteoporos Rep 10:22–27CrossRef
6.
Huntjens KM, Kosar S, van Geel TA, Geusens PP, Willems P, Kessels A, Brink P, van Helden S (2010) Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. Osteoporos Int 21:2075–2082PubMedCrossRefPubMedCentral
7.
Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179PubMedCrossRef
8.
van Helden S, Cals J, Kessels F, Brink P, Dinant GJ, Geusens P (2006) Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 17:348–354PubMedCrossRef
9.
von Friesendorff M, Besjakov J, Akesson K (2008) Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res 23:1832–1841CrossRef
10.
van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102PubMedCrossRef
11.
Sawalha S, Parker MJ (2012) Characteristics and outcome in patients sustaining a second contralateral fracture of the hip. J Bone Joint Surg (Br) 94:102–106CrossRef
12.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMedCrossRef
13.
Pearse EO, Redfern DJ, Sinha M, Edge AJ (2003) Outcome following a second hip fracture. Injury 34:518–521PubMedCrossRef
14.
Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedCrossRefPubMedCentral
15.
Alves SM, Economou T, Oliveira C, Ribeiro AL, Neves N, Gomez-Barrena E, Pina MF (2013) Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population based retrospective study. Bone 53:430–436PubMedCrossRef
16.
Turkington P, Madonald S, Elliott J, Beringer T (2012) Hip fracture in Northern Ireland, 1985–2010. Are age specific rates still rising? Ulster Med J 81:123–126PubMedPubMedCentral
17.
Melton LJ III, Therneau TM, Larson DR (1998) Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int 8:68–74PubMedCrossRef
18.
National Institute for Clinical Excellence (2005) Technology appraisal guidance 87 bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
19.
Omsland TK, Holvik K, Meyer HE, Center JR, Emaus N, Tell GS, Schei B, Tverdal A, Gjesdal CG, Grimnes G, Forsmo S, Eisman JA, Søgaard AJ (2012) Hip fractures in Norway 1999–2008: time trends in total incidence and second hip fracture rates: a NOREPOS study. Eur J Epidemiol 27:807–814PubMedCrossRef
20.
Melton LJ 3rd, Kearns AE, Atkinson EJ, Bolander ME, Achenbach SJ, Huddleston JM, Therneau TM, Leibson CL (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687–694PubMedCrossRefPubMedCentral
21.
Kanis JA, Mc Closkey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:407–413CrossRef
22.
Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2000) The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9:359–366PubMedCrossRef
23.
Warriner A, Patkar N, Curtis J, Delzell E, Gary L, Kilgore M, Saag K (2011) Which fractures are most attributable to osteoporosis? J Clin Epidemiol 64:46–53PubMedCrossRef
24.
Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU. Arch Osteoporos 6:59–155PubMedCrossRef
25.
Egan M, Jaglal S, Byrne K, Wells J, Stolee P (2008) Factors associated with a second hip fracture: a systematic review. Clin Rehabil 22:272–282PubMedCrossRef
26.
Colón-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S (2011) Clinical risk factors for recurrent fracture after hip fracture: a prospective study. Calcif Tissue Int 88:425–431PubMedCrossRef
27.
28.
Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960PubMedCrossRef
29.
Carbone LD, Johnson KC, Robbins J, Larson JC, Curb JD, Watson K, Gass M, Lacroix AZ (2010) Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J Bone Miner Res 25:873–881PubMedPubMedCentral
30.
31.
Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14–21PubMedCrossRef
32.
Budicǎ CR, Cristea ŞT, Panait GH (2010) Risk assessment of new fracture following fragility hip fracture. Arch Balk Med Union 45:40–48
33.
Curtis JR, Arora T, Matthews RS, Taylor A, Becker DJ, Colon-Emeric C, Kilgore ML, Morrisey MA, Saag KG, Safford MM, Warriner A, Delzell E (2010) Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 11:584–591PubMedCrossRefPubMedCentral
34.
Chen JS, Sambrook PN, Simpson JM, Cameron ID, Cumming RG, Seibel MJ et al (2009) Risk factors for hip fracture among institutionalised older people. Age Ageing 38:429–434PubMedCrossRef
35.
Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ (2008) How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis 59:1314–1321CrossRef
36.
Smith P, Ariti C, Bardsley M (2013) Focus on hip fracture: trends in emergency admission for fractured neck of femur, 2001 to 2011. Nuffield Trust/Health Foundation
37.
38.
Watson J, Wise L, Green J (2007) Prescribing hormone therapy for menopause, tibolone and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63:843–849PubMedCrossRef
39.
Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 35:319–326PubMedPubMedCentral
Metadata
Title
The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000–2010
Authors
D. Gibson-Smith
C. Klop
P. J. M. Elders
P. M. J. Welsing
N. van Schoor
H. G. M. Leufkens
N. C. Harvey
T. P. van Staa
F. de Vries
Publication date
01-11-2014
Publisher
Springer London
Published in
Osteoporosis International / Issue 11/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2799-x

Other articles of this Issue 11/2014

Osteoporosis International 11/2014 Go to the issue

Review

Management of osteoporosis of the oldest old

Short Communication

Radiation-free spinometry adds to the predictive power of historical height loss in clinical vertebral fracture assessment

Short Communication

The relationship between BPAQ-derived physical activity and bone density of middle-aged and older men

Original Article

Physical activity and 10-year incidence of self-reported vertebral fractures in Japanese women: The Japan Public Health Center-based Prospective Study

Original Article

Patient perceptions of provider barriers to post-fracture secondary prevention

Position Paper

Goal-directed treatment of osteoporosis in Europe